A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-Label Phase I Part to Assess the Safety and Tolerability of AZD2171 in Combination With FOLFOX Followed by a Phase II, Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy of AZD2171 in Combination With FOLFOX

Interventions: investigational material(s)
Generic name etc : AZD2171
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material : Oral
Primary outcome(s): Efficacy Primary Outcome Measures:- Progression of Metastatic Colorectal Cancer (mCRC) - PFS Secondary Outcome Measures: - Safety and tolerability [Time Frame: assessed at each visit]
Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment Study